2024
Cancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma
Giangreco G, Rullan A, Naito Y, Biswas D, Liu Y, Hooper S, Nenclares P, Bhide S, Chon U Cheang M, Chakravarty P, Hirata E, Swanton C, Melcher A, Harrington K, Sahai E. Cancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma. IScience 2024, 27: 110635. PMID: 39262776, PMCID: PMC11387794, DOI: 10.1016/j.isci.2024.110635.Peer-Reviewed Original ResearchTumor microenvironmentSquamous cell carcinoma cohortCancer cellsMacrophage chemo-attractantsSquamous cell carcinomaTumor-stroma crosstalkRecruitment of macrophagesExpression of CSF2Prognostic significanceCarcinoma cohortCell carcinomaPatient prognosisHB-EGFStromal fibroblastsCancer outcomesCancer progressionCancerMAPK signalingIndicator of signalingChemo-attractantsCellsFibroblastsCarcinomaExpressionEGFRPD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy
Davies D, Kamdar S, Woolf R, Zlatareva I, Iannitto M, Morton C, Haque Y, Martin H, Biswas D, Ndagire S, Munonyara M, Gillett C, O’Neill O, Nussbaumer O, Hayday A, Wu Y. PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy. Nature Cancer 2024, 5: 420-432. PMID: 38172341, PMCID: PMC10965442, DOI: 10.1038/s43018-023-00690-0.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitionPD-1T cellsProgrammed cell death protein 1Cell death protein 1PD-1 expressionResponse to TCR signalingPD-1 engagementT cell recognitionCancer immunotherapyTCR signalingTranscriptomic programsProtein 1CancerFunctional relevanceCellsImmunotherapyNeoantigensMelanomaPatientsOncology
2023
Quantifying the impact of immunotherapy on RNA dynamics in cancer
Usaite I, Biswas D, Dijkstra K, Watkins T, Pich O, Puttick C, Angelova M, Thakkar K, Hiley C, Birkbak N, Kok M, Zaccaria S, Wu Y, Litchfield K, Swanton C, Kanu N. Quantifying the impact of immunotherapy on RNA dynamics in cancer. Journal For ImmunoTherapy Of Cancer 2023, 11: e007870. PMID: 37914385, PMCID: PMC10626770, DOI: 10.1136/jitc-2023-007870.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitorsCheckpoint inhibitor treatmentBreast cancerOn-therapyImmune microenvironmentPre-therapyCancer typesPatients treated with checkpoint inhibitorsCheckpoint inhibitor therapyImpact of immunotherapyCancer immune microenvironmentSolid tumor typesMechanism of sensitizationClinical responseCombination therapyTumor typesIO targetsResponse ratePatientsBreastCancerImmunotherapyMelanomaMeta-analysesTherapy
2021
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu Y, Biswas D, Swanton C. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Seminars In Cancer Biology 2021, 84: 89-102. PMID: 33631295, PMCID: PMC9253787, DOI: 10.1016/j.semcancer.2021.02.013.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitor therapyCheckpoint inhibitorsIntratumour heterogeneityImmune surveillancePatient's response to immune checkpoint inhibitorsResponse to immune checkpoint inhibitorsCheckpoint inhibitor responseProportion of patientsStandard of carePredictive biomarkersStratify patientsImmune evasionDiagnostic accuracyInhibitor responseImmune systemMechanisms of genetic instabilityPatientsGenetic instabilityCancer evolutionTherapyCancerSurveillanceInhibitorsIntratumour